Motokazu Sato, Kohei Mizuta, Qinghong Han, Sei Morinaga, Byung Mo Kang, Yutaro Kubota, Ryosuke Mori, Anton Baranov, Keita Kobayashi, Daniel Ardjmand, Noritoshi Kobayashi, Michael Bouvet, Yasushi Ichikawa, Atsushi Nakajima, Robert M Hoffman
BACKGROUND/AIM: Colorectal cancer (CRC) is the third-leading cause of death in the world. Although the prognosis has improved due to improvement of chemotherapy, metastatic CRC is still a recalcitrant disease, with a 5-year survival of only 13%. Irinotecan (IRN) is used as first-line chemotherapy for patients with unresectable CRC. However, there are severe side effects, such as neutropenia and diarrhea, which are dose-limiting. We have previously shown that methionine restriction (MR), effected by recombinant methioninase (rMETase), lowered the effective dose of IRN of colon-cancer cells in vitro...
2024: In Vivo